A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs BGB 290 (Primary) ; BGB A317 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Fallopian tube cancer; Gastric cancer; Nerve sheath neoplasms; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 06 Jun 2017 Results (n=38; as of 16 Jan 2017) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Preliminary results (n=43) presented at the the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a BeiGene media release.
    • 05 Jun 2017 Preliminary results (n=43) published in a BeiGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top